Tachyplesin, an antimicrobial peptide from horseshoe crab, emerged as an effective anti-leishmanial agent against the intracellular parasite Leishmania donovani, offering a potential alternative to drug-resistant conventional treatments.
AMP vs parasiteTachyplesin — originally studied for antibacterial activity — proves effective against Leishmania parasites, expanding antimicrobial peptide applications to neglected tropical diseases
What the researchers found
Tachyplesin demonstrated effective anti-leishmanial activity against Leishmania donovani, the causative agent of visceral leishmaniasis, through a peptide-mediated parasite killing mechanism.
Why it matters
Visceral leishmaniasis kills tens of thousands annually and drug resistance is growing. AMPs like tachyplesin offer fundamentally different killing mechanisms that could overcome resistance to current antimonial and amphotericin B treatments.
The numbers in context
Tachyplesin: membrane disruption mechanism; cysteine-dependent activity; dual antimicrobial + cargo delivery function
How the study worked
In vitro and/or in vivo study testing tachyplesin antimicrobial peptide against Leishmania donovani. Anti-parasitic activity assessment.
Who was studied
Leishmania donovani promastigotes and amastigotes
What this study cannot tell us
Preclinical data. Tachyplesin delivery to intracellular parasites (inside macrophages) is challenging. Toxicity to host cells needs assessment. Manufacturing and cost concerns for tropical disease applications.
How to read the evidence
Low evidence grade: preclinical anti-parasitic testing. Important for neglected disease drug development.
When this study was published
Published 2021.
The bigger picture
Marine-derived antimicrobial peptides are a growing source of anti-parasitic leads. Tachyplesin adds to the evidence that AMPs can target not just bacteria but also the protozoan parasites causing neglected tropical diseases.
Questions still open
- Can tachyplesin reach parasites hiding inside macrophages?
- What is tachyplesin's selectivity index for Leishmania versus human cells?
- Could tachyplesin be combined with existing anti-leishmanial drugs?
Common questions
What is tachyplesin?
Why is visceral leishmaniasis hard to treat?
Read the original research
Peptide-mediated leishmaniasis management strategy: Tachyplesin emerges as an effective anti-leishmanial peptide against Leishmania donovani.
Biochimica et biophysica acta. Biomembranes, 1863(8), 183629
Citation
Kumar, Vivek; Chugh, Archana. (2021). Peptide-mediated leishmaniasis management strategy: Tachyplesin emerges as an effective anti-leishmanial peptide against Leishmania donovani.. Biochimica et biophysica acta. Biomembranes, 1863(8), 183629. https://doi.org/10.1016/j.bbamem.2021.183629